Acasti Pharma (ACST) Swings to Q3 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Neptune Announces Third Quarter Results
January 13, 2015 5:05 PM ESTLAVAL, Quebec, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq: NEPT) (TSX: NTB), announces its consolidated financial results for the three and nine month periods ended November 30, 2014.
"We made solid progress on all fronts this past quarter, completing the ramp-up of production at our Sherbrooke plant, resuming shipments of Neptune manufactured krill oil, and announcing the appointment of nutraceutical industry leader, Mr. Jim Hamilton, as Neptune's new President and CEO, effective February 2015," highlighted Mr. André Godin, Interim President and Chief Executive Officer... More
Acasti Announces Third Quarter Results
January 13, 2015 5:05 PM ESTLAVAL, Quebec, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq: ACST) (TSX-V: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the three and nine-months ended November 30, 2014.
The Corporation has made important progress in its drug development program to obtain regulatory approval to distribute and market CaPre® as a prescription drug.... More
